Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageInnoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, “FF/VI”) and ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, “UMEC/VI”).
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Jun 2026 · $121.4MThe company’s own SEC segment disclosure.
- Royalty$56.3M46%
- Xacduro$22.4M18%
- Giapreza$22.3M18%
- License And Other$11.5M9%
- Xerava$6.7M6%
- Cost Reimbursement$1.8M1%
- Other (1)$351.0K0%
Innoviva, Inc. (INVA) reported revenue of $98M in Q1 2026 (quarter ended Mar 31, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $187M (190% of revenue). For the full year FY2025, revenue was $411M (+15% year on year) and net income $271M. Its largest product in Jun 2026 was Royalty at $56M, 46% of the disclosed total, well ahead of Xacduro at 18%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #54 of 143 by Smart Score